Morphine-induced osteolysis and hypersensitivity is mediated through toll-like receptor-4 in a murine model of metastatic breast cancer
Authors:
- Austen L. ThompsonATAusten L. Thompson
- Shaness A. GrenaldSGShaness A. Grenald
- Haley A. CicconeHCHaley A. Ciccone
- Dieter MohtyDMDieter Mohty
- Angela F. SmithASAngela F. Smith
- Deziree L. ColemanDCDeziree L. Coleman
- Erfan BahramnejadEBErfan Bahramnejad
- Erick De LeonELErick De Leon
- Logan Kasper-ConellaLKLogan Kasper-Conella
- Jennifer L. UhrlabJUJennifer L. Uhrlab
- David S. MargolisDMDavid S. Margolis
- Daniela SalveminiDSDaniela Salvemini
Open Access
- 15 June 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Pain
- Vol. 164 (11) , 2463-2476
Abstract
The propensity for breast cancer to metastasize to bone is coupled to the most common complaint among breast cancer patients: bone pain. Classically, this type of pain is treated using escalating doses of opioids, which lack long-term efficacy due to analgesic tolerance, opioid-induced hypersensitivity, and have recently been linked to enhanced bone loss. To date, the molecular mechanisms underlying these adverse effects have not been fully explored. Using an immunocompetent murine model of metastatic breast cancer, we demonstrated that sustained morphine infusion induced a significant increase in osteolysis and hypersensitivity within the ipsilateral femur through the activation of toll-like receptor-4 (TLR4). Pharmacological blockade with TAK242 (resatorvid) as well as the use of a TLR4 genetic knockout ameliorated the chronic morphine-induced osteolysis and hypersensitivity. Genetic MOR knockout did not mitigate chronic morphine hypersensitivity or bone loss. In vitro studies using RAW264.7 murine macrophages precursor cells demonstrated morphine-enhanced osteoclastogenesis that was inhibited by the TLR4 antagonist. Together, these data indicate that morphine induces osteolysis and hypersensitivity that are mediated, in part, through a TLR4 receptor mechanism.Keywords
This publication has 75 references indexed in Scilit:
- Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapyBMJ Open, 2013
- Morphine activates neuroinflammation in a manner parallel to endotoxinProceedings of the National Academy of Sciences, 2012
- Prospective evaluation of bone mineral density among middle-aged HIV-infected and uninfected women: Association between methadone use and bone lossMaturitas, 2011
- Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer painNeuroscience, 2010
- Novel functions for NFκB: inhibition of bone formationNature Reviews Rheumatology, 2010
- A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone lossLife Sciences, 2010
- Evidence that opioids may have toll-like receptor 4 and MD-2 effectsBrain, Behavior, and Immunity, 2010
- Inhibition of osteoblastic bone formation by nuclear factor-κBNature Medicine, 2009
- Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancerPain, 2007
- NF-κB: linking inflammation and immunity to cancer development and progressionNature Reviews Immunology, 2005